DILLON VEAL: Open Payments
NPI 1528649332 · WAYCROSS, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,521 in 86 payments from 19 companies in 2025. Trend: 2023 $1,303 · 2024 $1,518 · 2025 $1,521
Food & beverage: $1,521
| Company | Payments | Amount |
|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | 13 | $275 |
| ABBVIE INC. | 12 | $228 |
| PFIZER INC. | 11 | $164 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 12 | $142 |
| Axsome Therapeutics, Inc. | 6 | $129 |
| Lilly USA, LLC | 5 | $85 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 4 | $67 |
| Vanda Pharmaceuticals Inc. | 2 | $61 |
| Novo Nordisk Inc | 3 | $51 |
| Antares Pharma, Inc. | 3 | $48 |
Products named: Kerendia, NURTEC ODT, CAPLYTA, VRAYLAR, Sunosi, MOUNJARO, XIFAXAN, FANAPT.
Industry payments across GA — which companies pay providers there.
